Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16264393 | 0.91 | CYP2C9 (0.54) | CYP2C9MAPTGSK3BKDM4ETDP1 | |
| SCHEMBL16264633 | 0.90 | CYP2C9 (0.45) | CYP2C9MAPTGSK3BLMNAKDM4E | |
| SCHEMBL16264472 | 0.89 | CYP2C9 (0.58) | CYP2C9LMNAKDM4ETDP1L3MBTL1 | |
| SCHEMBL16264546 | 0.89 | CYP2C9 (0.58) | CYP2C9KDM4ETDP1L3MBTL1MAPK10 | |
| SCHEMBL17903908 | 0.87 | CYP2C9 (0.56) | CYP2C9LMNAKDM4EMAPK10NPC1 | |
| SCHEMBL16264468 | 0.86 | CYP2C9 (0.55) | CYP2C9KDM4ETDP1L3MBTL1MAPK10 | |
| SCHEMBL17906100 | 0.86 | CYP2C9 (0.55) | CYP2C9KDM4ETDP1L3MBTL1MAPK10 | |
| SCHEMBL16264474 | 0.86 | CYP2C9 (0.55) | CYP2C9LMNAKDM4EMAPK10NPC1 | |
| SCHEMBL17903912 | 0.85 | KCNH2 (0.43) | CYP2C9MAPTGSK3BBRAF | |
| SCHEMBL16264480 | 0.85 | CYP2C9 (0.51) | CYP2C9LMNAKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| WO-2014190199-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | FNTB, PGLS, EP300 | CYP2C9 1792/4885MAPT 1082/4885GSK3B 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.